Interferon-ε protects the female reproductive tract from viral and bacterial infection

Science

Volumn 339, Issue 6123, 2013, Pages

  Fung, Ka Yee ^a   Mangan, Niamh E ^a   Cumming, Helen ^a   Horvat, Jay C ^b   Mayall, Jemma R ^b   Stifter, Sebastian A ^a   De Weerd, Nicole ^a   Roisman, Laila C ^a   Rossjohn, Jamie ^a   Robertson, Sarah A ^c   Schjenken, John E ^c   Parker, Belinda ^d,e   Gargett, Caroline E ^a   Nguyen, Hong P T ^a   Carr, Daniel J ^f   Hansbro, Philip M ^b   Hertzog, Paul J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSILON INTERFERON; INTERFERON; UNCLASSIFIED DRUG;

CHLAMYDIA; CHLAMYDIACEAE INFECTION; EPITHELIUM CELL; GYNECOLOGIC DISEASE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HORMONAL REGULATION; HUMAN; INFECTION SENSITIVITY; INNATE IMMUNITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 84874396777     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1233321     Document Type: Note

References (27)

1. S. Hervas-Stubbs et al., Clin. Cancer Res. 17, 2619 (2011).
2. A. Isaacs, J. Lindenmann, Proc. R. Soc. London Ser. B Biol. Sci. 147, 258 (1957).
3. M. P. Hardy, C. M. Owczarek, L. S. Jermiin, M. Ejdebäck, P. J. Hertzog, Genomics 84, 331 (2004).
4. K. Honda, A. Takaoka, T. Taniguchi, Immunity 25, 349 (2006).
5. M. Sato et al., Immunity 13, 539 (2000).
6. N. A. de Weerd, S. A. Samarajiwa, P. J. Hertzog, J. Biol. Chem. 282, 20053 (2007).
7. L. Alexopoulou, A. C. Holt, R. Medzhitov, R. A. Flavell, Nature 413, 732 (2001).
8. S. E. Doyle et al., J. Immunol. 170, 3565 (2003).
9. V. Hornung, E. Latz, Nat. Rev. Immunol. 10, 123 (2010).
10. M. V. Patel, M. Ghosh, J. V. Fahey, C. R. Wira, PLoS ONE 7, e35654 (2012).
11. L. A. Salamonsen, in The Endometrium, J. D. Aplin, A. T. Fazleabas, S. R. Glasser, L. C. Giudice, Eds. (Informa Healthcare, London, ed. 2, 2008), pp. 25-45.
12. M. Thapa, D. J. Carr, J. Virol. 83, 9486 (2009).
13. K. W. Beagley, W. M. Huston, P. M. Hansbro, P. Timms, Crit. Rev. Immunol. 29, 275 (2009).
14. World Health Organization (WHO), Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections Overview and Estimates (WHO, Geneva, 2001).
15. K. L. Asquith et al., PLoS Pathog. 7, e1001339 (2011).
16. C. T. Tseng, R. G. Rank, Infect. Immun. 66, 5867 (1998).
17. A. Devitt, P. A. Lund, A. G. Morris, J. H. Pearce, Infect. Immun. 64, 3951 (1996).
18. S. P. Lad, E. Y. Fukuda, J. Li, L. M. de la Maza, E. Li, J. Immunol. 174, 7186 (2005).
19. U. M. Nagarajan, D. M. Ojcius, L. Stahl, R. G. Rank, T. Darville, J. Immunol. 175, 450 (2005).
20. U. M. Nagarajan et al., Infect. Immun. 76, 4642 (2008).
21. B. A. Austin, C. M. James, P. Härle, D. J. Carr, Biol. Proced. Online 8, 55 (2006).
22. C. D. Conrady, W. P. Halford, D. J. Carr, J. Virol. 85, 1625 (2011).
23. J. M. Baeten et al., Am. J. Obstet. Gynecol. 185, 380 (2001).
24. C. C. Wang, J. K. Kreiss, M. Reilly, J. Acquir. Immune Defic. Syndr. 21, 51 (1999).
25. R. P. Morrison, H. D. Caldwell, Infect. Immun. 70, 2741 (2002).
26. M. B. Parr et al., Lab. Invest. 70, 369 (1994).
27. C. Thomas et al., Cell 146, 621 (2011).